Discontinuity-Reference-Cited by-同舟云学术

Discontinuity

Published:2017-11 Issue:19 Volume:70 Page:2345-2348
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Virmani Renu,Jinnouchi Hiroyuki,Finn Aloke V.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference16 articles.

1. 10-Year clinical outcome after randomization to treatment by sirolimus- or paclitaxel-eluting coronary stents;Galloe;J Am Coll Cardiol,2017

2. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease;Stone;N Engl J Med,2010

3. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy;Ali;Lancet,2017

4. Ellis SG. Everolimus-eluting bioresorbable vascular scaffolds in patients with coronary artery disease: Presented at: American College of Cardiology (ACC) Annual Scientific Session. Washington, DC; March 18, 2017.

5. Bioresorbable scaffolds versus metallic stents in routine PCI;Wykrzykowska;N Engl J Med,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New opportunities for bioresorbable scaffold technology;AsiaIntervention;2023-09

2. Challenges of the newer generation of resorbable magnesium scaffolds: Lessons from failure mechanisms of the past generation;Journal of Cardiology;2023-02

3. Scaffold underexpansion and late lumen loss after bioresorbable scaffold implantation: Insights from ABSORB JAPAN trial;IJC Heart & Vasculature;2020-12

4. Magnetic resonance (MR) safety and compatibility of a novel iron bioresorbable scaffold;Bioactive Materials;2020-06

5. Preclinical Evaluation of a Novel Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold in Porcine Coronary Artery at 6 Months;JACC: Cardiovascular Interventions;2019-02